Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Huang-Chih ChangKuo-Tung HuangChia-Cheng TsengYu-Mu ChenChien-Hao LaiYu-Ping ChangYung-Che ChenHung-Yi ChuangChin-Chou WangPublished in: Thoracic cancer (2023)
This real-world evidence shows that afatinib confers better survival than other first-line EGFR-TKIs in East Asian patients with advanced NSCLC.